Associated Papers
CDKL3 is a targetable regulator of cell cycle progression in cancers.
Zhang H et al.
The Journal of Clinical Investigation, 2024
A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity.
Nataraj SE et al.
Cell Cycle (georgetown, Tex.), 2021
Combined Inactivation of Pocket Proteins and APC/CCdh1 by Cdk4/6 Controls Recovery from DNA Damage in G1 Phase.
Shaltiel IA et al.
Cells, 2021
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y et al.
Nature Communications, 2019
CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.
Chen H et al.
The Journal of Biological Chemistry, 2017
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells.
The I et al.
Nature Communications, 2015
Select a paper to view details